Literature DB >> 3966979

Factors influencing the chemosensitization of melphalan by misonidazole.

V S Randhawa, F A Stewart, J Denekamp, M R Stratford.   

Abstract

The effect of melphalan alone or combined with various schedules of misonidazole (MISO) has been tested on a murine fibrosarcoma. The tumoricidal effect has been determined using the growth delay assay. Large single doses (500-1000 mgkg-1) of MISO enhanced the anti-tumour effect of melphalan, especially at high melphalan doses. This was accompanied by a drop in body and tumour temperature and an increase in the melphalan half-life. The MISO-induced hypothermia was prevented in one experiment by keeping the mice in an ambient temperature of 35 degrees C for 3 h. This reduced the exposure to melphalan but did not diminish the cytotoxic effect of the drug combination. Chronic administration of MISO for an 8 h period gave no enhancement of melphalan damage, whether melphalan was given half-way through or at the end of the period of dosing. It seems that a threshold tumour concentration of MISO, in excess of 70 micrograms g-1, is needed for enhancement of melphalan cytotoxicity; prolonged exposures to very low doses are ineffective.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966979      PMCID: PMC1977037          DOI: 10.1038/bjc.1985.32

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

3.  Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.

Authors:  R D Clutterbuck; J L Millar; T J McElwain
Journal:  Am J Clin Oncol       Date:  1982-02       Impact factor: 2.339

4.  The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity.

Authors:  D G Hirst; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

5.  The nitroimidazoles as radiosensitizers and cytotoxic agents.

Authors:  E J Hall; R Miller; M Astro; F Rini
Journal:  Br J Cancer Suppl       Date:  1978-06

6.  The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man.

Authors:  I J Stratford; G E Adams
Journal:  Br J Radiol       Date:  1978-09       Impact factor: 3.039

7.  Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.

Authors:  T C Stephens; V D Courtenay; J Mills; J H Peacock; C M Rose; D Spooner
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

8.  The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Authors:  M Hinchliffe; N J McNally; M R Stratford
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

9.  Enhancement of the effect of cytotoxic drugs by radiosensitizers.

Authors:  W M Martin; N J McNally; J De Ronde
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

10.  Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.

Authors:  P Twentyman; P Workman
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

View more
  7 in total

Review 1.  Vascular attack as a therapeutic strategy for cancer.

Authors:  J Denekamp
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

2.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Misonidazole reduces blood flow in two experimental murine tumours.

Authors:  J C Murray; V S Randhawa
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

5.  The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours.

Authors:  P K Quinn; M C Bibby; J A Cox; S M Crawford
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

6.  The effects of melphalan and misonidazole on the vasculature of a murine sarcoma.

Authors:  J C Murray; V Randhawa; J Denekamp
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

7.  Oxygen dependence for chemosensitization by misonidazole.

Authors:  L Roizin-Towle; E J Hall; J P Pirro
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.